Sino Biopharmaceutical Limited (SEHK: 1177), known as Sino Biopharm, is a leading research and development-driven pharmaceutical conglomerate headquartered in Hong Kong. Founded in 2000 and listed on the Hong Kong Stock Exchange, the company develops, manufactures, and markets biopharmaceuticals, modernized Chinese medicines, and chemical drugs primarily in China.
Its portfolio targets key therapeutic areas including oncology, hepatology, respiratory diseases, cardiovascular conditions, and others such as tumors, liver diseases, and surgery/analgesia. Major subsidiaries include Chia Tai Tianqing Pharmaceutical Group and invoX Pharma. With a focus on innovation, Sino Biopharm maintains advanced R&D platforms and production facilities across China.
Also known as 中国生物制药有限公司.
None yet. When a new project in the record names Sino Biopharm as owner, partner or investor, it shows here.
Pooled Phase III trials: 26% functional cure in patients with ≤1000 IU/mL HBsAg; 49% reached qHBsAg ≤100 IU/mL at 1 year; acceptable safety; regulatory reviews and anticipated Q3 2026 decisions.
Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
2025 revenue +16.7% to RMB21.8bn; gross margin +500bps to 46%; EBITDA +38%; net profit +45%; 209 new integrated projects; backlog US$23.7bn; bi-/multi-specifics >120% growth
